Delphi Advisor to Enorama Pharma in rights issue

Delphi has assisted Enorama Pharma AB (publ) in connection with Enorama Pharma’s execution of a rights issue of 6,665,386 shares. Through the rights issue, Enorama Pharma is provided with approximately 19.33 MSEK before issue costs.

Enorama Pharma’s vision is to help the world make smarter nicotine choices by being a global developer, producer, and supplier of consumer-friendly oral nicotine products. The company intends to expand through product and brand development as well as by establishing strategically important partnerships.

Delphi’s team consisted of Ludvig Borg, Elfie Ekegren Franzetti, and Micael Karlsson.